Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Leblanc

Showing results (71-80 of 155) with videos related to

Pageof 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420Stephen K Williamson, James Moon, Chao H Huang, et al.
Journal of the National Cancer Institute|March 15, 2014
Comparison of survival outcomes among cancer patients treated in and out of clinical trialsJoseph M Unger, William E Barlow, Diane P Martin, et al.
Journal of the National Cancer Institute|March 22, 2023
Risk prediction of hepatitis B or C or HIV among newly diagnosed cancer patientsJoseph M Unger, Cathee Till, Jessica P Hwang, et al.
Journal of the National Cancer Institute|December 26, 2014
The diffusion of docetaxel in patients with metastatic prostate cancerJoseph M Unger, Dawn L Hershman, Diane Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2006
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911Oliver W Press, Joseph M Unger, Rita M Braziel, et al.
Investigational New Drugs|November 26, 2009
Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618Susanne M Arnold, James Moon, Stephen K Williamson, et al.
Cancer|March 2, 2005
Estimated impact of the Prostate Cancer Prevention Trial on population mortalityJoseph M Unger, Ian M Thompson, Michael LeBlanc, et al.
JCO Oncology Advances|April 23, 2025
SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low-Tumor Burden Follicular LymphomaNilanjan Ghosh, Shay Bellasea, Hongli Li, et al.
Journal of Pharmacy Practice|September 26, 2013
Outcomes assessment of a pharmacist-directed seamless care program in an ambulatory oncology clinicScott J Edwards, Rick Abbott, Jonathan Edwards, et al.
Cancer|July 27, 2012
Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350Daruka Mahadevan, Joseph M Unger, Catherine M Spier, et al.
Pageof 16

Showing results (71-80 of 155) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420Stephen K Williamson, James Moon, Chao H Huang, et al.
Journal of the National Cancer Institute|March 15, 2014
Comparison of survival outcomes among cancer patients treated in and out of clinical trialsJoseph M Unger, William E Barlow, Diane P Martin, et al.
Journal of the National Cancer Institute|March 22, 2023
Risk prediction of hepatitis B or C or HIV among newly diagnosed cancer patientsJoseph M Unger, Cathee Till, Jessica P Hwang, et al.
Journal of the National Cancer Institute|December 26, 2014
The diffusion of docetaxel in patients with metastatic prostate cancerJoseph M Unger, Dawn L Hershman, Diane Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2006
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911Oliver W Press, Joseph M Unger, Rita M Braziel, et al.
Investigational New Drugs|November 26, 2009
Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618Susanne M Arnold, James Moon, Stephen K Williamson, et al.
Cancer|March 2, 2005
Estimated impact of the Prostate Cancer Prevention Trial on population mortalityJoseph M Unger, Ian M Thompson, Michael LeBlanc, et al.
JCO Oncology Advances|April 23, 2025
SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low-Tumor Burden Follicular LymphomaNilanjan Ghosh, Shay Bellasea, Hongli Li, et al.
Journal of Pharmacy Practice|September 26, 2013
Outcomes assessment of a pharmacist-directed seamless care program in an ambulatory oncology clinicScott J Edwards, Rick Abbott, Jonathan Edwards, et al.
Cancer|July 27, 2012
Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350Daruka Mahadevan, Joseph M Unger, Catherine M Spier, et al.
Pageof 16